Seattle Genetics, Astellas ally with Merck in trial collaboration
|Seattle Genetics Inc. and Astellas Pharma Inc. are teaming up with Merck & Co. Inc. in a trial collaboration to evaluate the combination of Seattle Genetics/Astellas' enfortumab vedotin and Merck’s Keytruda (pembrolizumab) in patients with previously untreated metastatic urothelial cancer.|
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.